Natera

Natera, Inc. is a global leader in cell-free DNA (cfDNA) testing, focusing on women's health, oncology, and organ health. The company utilizes proprietary bioinformatics, molecular biology, and AI-driven platforms to provide non-invasive genetic diagnostics. Founded in 2004 and rebranded in 2012, Natera has grown significantly, employing over 2,600 people and operating CLIA-certified and CAP-accredited labs in Texas and California. Natera's key products include the Panorama™ non-invasive prenatal test, which analyzes fetal DNA for chromosomal abnormalities, and the Signatera™ test for monitoring cancer through circulating tumor DNA. In organ health, the Prospera™ test assesses kidney transplant rejection using donor-derived cfDNA. Natera's commitment to innovation is backed by extensive research, with over 300 peer-reviewed publications and participation in major clinical trials. The company aims to enhance early detection of genetic diseases and improve standards of care worldwide.